[go: up one dir, main page]

MXPA03001039A - Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina. - Google Patents

Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina.

Info

Publication number
MXPA03001039A
MXPA03001039A MXPA03001039A MXPA03001039A MXPA03001039A MX PA03001039 A MXPA03001039 A MX PA03001039A MX PA03001039 A MXPA03001039 A MX PA03001039A MX PA03001039 A MXPA03001039 A MX PA03001039A MX PA03001039 A MXPA03001039 A MX PA03001039A
Authority
MX
Mexico
Prior art keywords
administration
antiviral
erythropoeitin
viral
epo
Prior art date
Application number
MXPA03001039A
Other languages
English (en)
Inventor
Peter Bowers
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA03001039A publication Critical patent/MXPA03001039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion provee metodos que usan eritropoyetina para mejorar la tolerancia de regimenes quimioterapeuticos antivirales y antitumorales que contienen interferon; la invencion describe tambien metodos mejorados para tratar infeccion cronica por HCV ajustando la dosis de ribavirina para adaptar la dosis activa del farmaco, mientras se sustentan los niveles de hemoglobina en el paciente con EPO; la presente invencion provee tambien regimenes de dosificacion antiviral, en particular infeccion cronica por HCV, que comprenden la administracion de un medicamento antiviral que contiene interferon, EPO, y un compuesto que reduce la cantidad del factor de necrosis tumoral activo en el sujeto.
MXPA03001039A 2000-08-02 2001-08-01 Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina. MXPA03001039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253800P 2000-08-02 2000-08-02
PCT/US2001/024426 WO2002010743A1 (en) 2000-08-02 2001-08-01 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin

Publications (1)

Publication Number Publication Date
MXPA03001039A true MXPA03001039A (es) 2004-09-10

Family

ID=22832621

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001039A MXPA03001039A (es) 2000-08-02 2001-08-01 Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina.

Country Status (17)

Country Link
US (1) US20020052317A1 (es)
EP (1) EP1325324A4 (es)
JP (1) JP2004505114A (es)
KR (1) KR20030043924A (es)
CN (1) CN1466680A (es)
AU (1) AU2001281047A1 (es)
BR (1) BR0113179A (es)
CA (1) CA2417550A1 (es)
CZ (1) CZ2003311A3 (es)
HK (1) HK1054432A1 (es)
HU (1) HUP0303056A2 (es)
MX (1) MXPA03001039A (es)
PL (1) PL365664A1 (es)
RU (1) RU2003102887A (es)
WO (1) WO2002010743A1 (es)
YU (1) YU7503A (es)
ZA (1) ZA200301634B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6833351B2 (en) * 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
JP2004537569A (ja) * 2001-08-02 2004-12-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリスロポエチンおよび抗−腫瘍壊死因子アルファ組み合わせ療法
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
CA2525568C (en) * 2003-05-12 2017-07-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
BRPI0411172A (pt) * 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
CA2548454C (en) * 2003-12-04 2013-12-31 Kyowa Hakko Kogyo Co., Ltd. Medicament comprising recombinant antibody against chemokine receptor ccr4
MX2007005777A (es) * 2004-11-11 2007-07-20 Affymax Inc Peptidos novedosos que se unen al receptor de eritropoietina.
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8563253B2 (en) * 2006-08-30 2013-10-22 Metanomics Gmbh Means and method for diagnosing hemolytic anemia
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US10183968B2 (en) * 2011-10-31 2019-01-22 Merck Sharp & Dohme Corp. Methods of preparing lyophilized spherical-shaped pellets of biological materials
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
EP1325324A1 (en) 2003-07-09
WO2002010743A1 (en) 2002-02-07
JP2004505114A (ja) 2004-02-19
US20020052317A1 (en) 2002-05-02
ZA200301634B (en) 2004-06-22
AU2001281047A1 (en) 2002-02-13
PL365664A1 (en) 2005-01-10
CA2417550A1 (en) 2002-02-07
EP1325324A4 (en) 2004-11-10
KR20030043924A (ko) 2003-06-02
BR0113179A (pt) 2004-06-22
YU7503A (sh) 2006-03-03
HUP0303056A2 (hu) 2003-12-29
HK1054432A1 (zh) 2003-11-28
CZ2003311A3 (cs) 2004-04-14
CN1466680A (zh) 2004-01-07
RU2003102887A (ru) 2004-07-27

Similar Documents

Publication Publication Date Title
MXPA03001039A (es) Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina.
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
Vazhappilly et al. Current methodologies to refine bioavailability, delivery, and therapeutic efficacy of plant flavonoids in cancer treatment
US12156863B2 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US20220118119A1 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
NZ631155A (en) Combination of two antivirals for treating hepatitis c
US20210338686A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
AU2018252003A1 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
BR112022009283A2 (pt) Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina
IL273398B2 (en) History of 4'-fluoro-2'-methyl-modified nucleosides as inhibitors of HCV RNA replication
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2003007931A1 (fr) Derives de sulfonamide
Blakeley et al. Chemotherapy with cytotoxic and cytostatic agents in brain cancer
KR102258152B1 (ko) 혈액암 치료제
JP2011514355A5 (es)
DK1488795T3 (da) Midler til behandling af lungecancer
JPS63203619A (ja) 抗腺がん剤
Abele et al. Phase I study of cyclohexylamine and lysine salt of mafosfamide
Blagden et al. First in human Phase I study of NUC-3373, a nucleotide analogue designed to overcome fluoropyrimidine drug resistance mechanisms
PE20020955A1 (es) Dosificacion metronomica de taxanos
WO2004096239A1 (en) Method for administration of troxacitabine
Hynes et al. Effects of 5, 8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil
RU2001122947A (ru) Способ лечения злокачественных опухолей
Chen et al. Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells
RU2009140983A (ru) Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное